BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 917 filers reported holding BAXTER INTL INC in Q4 2013. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $231,000 | -71.6% | 2,977 | -68.5% | 0.04% | -57.3% |
Q4 2021 | $812,000 | -3.7% | 9,454 | -9.9% | 0.08% | -10.9% |
Q3 2021 | $843,000 | -35.6% | 10,489 | -35.5% | 0.09% | -35.7% |
Q2 2021 | $1,308,000 | -38.5% | 16,264 | -35.5% | 0.14% | -42.8% |
Q1 2021 | $2,126,000 | -65.1% | 25,215 | -66.8% | 0.25% | -68.2% |
Q4 2020 | $6,087,000 | -32.1% | 75,873 | -31.9% | 0.78% | -34.0% |
Q3 2020 | $8,965,000 | -5.8% | 111,477 | +0.8% | 1.19% | -14.3% |
Q2 2020 | $9,522,000 | +7.5% | 110,583 | +1.3% | 1.39% | -11.0% |
Q1 2020 | $8,860,000 | -0.4% | 109,124 | +2.6% | 1.56% | +20.6% |
Q4 2019 | $8,896,000 | -3.1% | 106,384 | +1.4% | 1.29% | -10.3% |
Q3 2019 | $9,180,000 | +5.7% | 104,957 | -1.0% | 1.44% | +5.0% |
Q2 2019 | $8,683,000 | +5.1% | 106,019 | +4.4% | 1.37% | +0.8% |
Q1 2019 | $8,260,000 | +30.2% | 101,597 | +5.4% | 1.36% | +11.8% |
Q4 2018 | $6,344,000 | -10.0% | 96,385 | +5.4% | 1.22% | +4.2% |
Q3 2018 | $7,051,000 | +7.1% | 91,467 | +2.6% | 1.17% | +1.4% |
Q2 2018 | $6,585,000 | +15.2% | 89,180 | +1.4% | 1.15% | +11.5% |
Q1 2018 | $5,718,000 | +2.4% | 87,910 | +1.8% | 1.03% | +1.5% |
Q4 2017 | $5,584,000 | +2.3% | 86,376 | -0.7% | 1.02% | -2.9% |
Q3 2017 | $5,457,000 | +2.5% | 86,973 | -1.1% | 1.05% | -2.2% |
Q2 2017 | $5,325,000 | +16.2% | 87,956 | -0.4% | 1.07% | +11.8% |
Q1 2017 | $4,581,000 | +25.9% | 88,330 | +7.6% | 0.96% | +19.7% |
Q4 2016 | $3,639,000 | -0.7% | 82,062 | +6.7% | 0.80% | -2.3% |
Q3 2016 | $3,663,000 | +8.8% | 76,937 | +3.3% | 0.82% | +6.9% |
Q2 2016 | $3,368,000 | +13.6% | 74,476 | +3.2% | 0.77% | +6.7% |
Q1 2016 | $2,965,000 | +19.7% | 72,187 | +11.2% | 0.72% | +14.3% |
Q4 2015 | $2,477,000 | +19.1% | 64,918 | +2.5% | 0.63% | -0.8% |
Q3 2015 | $2,080,000 | -50.4% | 63,332 | +5.7% | 0.64% | -45.8% |
Q2 2015 | $4,191,000 | +0.1% | 59,938 | -2.0% | 1.17% | +0.8% |
Q1 2015 | $4,188,000 | -5.4% | 61,141 | +1.2% | 1.16% | -16.6% |
Q4 2014 | $4,427,000 | +2.1% | 60,399 | -0.1% | 1.39% | -4.3% |
Q3 2014 | $4,338,000 | +0.5% | 60,450 | +1.3% | 1.46% | -2.6% |
Q2 2014 | $4,316,000 | -3.1% | 59,697 | -1.4% | 1.49% | -11.5% |
Q1 2014 | $4,455,000 | -11.3% | 60,543 | -16.2% | 1.69% | -14.0% |
Q4 2013 | $5,024,000 | +5.3% | 72,235 | -0.5% | 1.96% | -2.6% |
Q3 2013 | $4,771,000 | -6.3% | 72,621 | -1.2% | 2.02% | -12.0% |
Q2 2013 | $5,094,000 | – | 73,535 | – | 2.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |